237 related articles for article (PubMed ID: 20921909)
1. A trial to assess the efficacy of glutamic acid in prevention of vincristine-induced neurotoxicity in pediatric malignancies: a pilot study.
Mokhtar GM; Shaaban SY; Elbarbary NS; Fayed WA
J Pediatr Hematol Oncol; 2010 Nov; 32(8):594-600. PubMed ID: 20921909
[TBL] [Abstract][Full Text] [Related]
2. Amelioration of vincristine neurotoxicity by glutamic acid.
Jackson DV; Wells HB; Atkins JN; Zekan PJ; White DR; Richards F; Cruz JM; Muss HB
Am J Med; 1988 Jun; 84(6):1016-22. PubMed ID: 2897788
[TBL] [Abstract][Full Text] [Related]
3. Glutamic acid not beneficial for the prevention of vincristine neurotoxicity in children with cancer.
Bradfield SM; Sandler E; Geller T; Tamura RN; Krischer JP
Pediatr Blood Cancer; 2015 Jun; 62(6):1004-10. PubMed ID: 25545757
[TBL] [Abstract][Full Text] [Related]
4. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.
Harnicar S; Adel N; Jurcic J
J Oncol Pharm Pract; 2009 Sep; 15(3):175-82. PubMed ID: 19282418
[TBL] [Abstract][Full Text] [Related]
5. Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia.
Jeng MR; Feusner J
Pediatr Hematol Oncol; 2001 Mar; 18(2):137-42. PubMed ID: 11255732
[TBL] [Abstract][Full Text] [Related]
6. Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia.
Reinders-Messelink HA; Van Weerden TW; Fock JM; Gidding CE; Vingerhoets HM; Schoemaker MM; Göeken LN; Bökkerink JP; Kamps WA
Eur J Paediatr Neurol; 2000; 4(5):225-33. PubMed ID: 11030069
[TBL] [Abstract][Full Text] [Related]
7. Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristine.
Hartman A; van den Bos C; Stijnen T; Pieters R
Cancer; 2006 Mar; 106(6):1395-401. PubMed ID: 16453332
[TBL] [Abstract][Full Text] [Related]
8. Vincristine neurotoxicity in the presence of hereditary neuropathy.
Trobaugh-Lotrario AD; Smith AA; Odom LF
Med Pediatr Oncol; 2003 Jan; 40(1):39-43. PubMed ID: 12426685
[No Abstract] [Full Text] [Related]
9. Effect of azole antifungal therapy on vincristine toxicity in childhood acute lymphoblastic leukaemia.
van Schie RM; Brüggemann RJ; Hoogerbrugge PM; te Loo DM
J Antimicrob Chemother; 2011 Aug; 66(8):1853-6. PubMed ID: 21652620
[TBL] [Abstract][Full Text] [Related]
10. Vincristine and intestinal pseudo-obstruction in children: report of 5 cases, literature review, and suggested management.
Diezi M; Nydegger A; Di Paolo ER; Kuchler H; Beck-Popovic M
J Pediatr Hematol Oncol; 2010 May; 32(4):e126-30. PubMed ID: 20418785
[TBL] [Abstract][Full Text] [Related]
11. Glutamic acid modification of vincristine toxicity.
Jackson DV; Rosenbaum DL; Carlisle LJ; Long TR; Wells HB; Spurr CL
Cancer Biochem Biophys; 1984 Sep; 7(3):245-52. PubMed ID: 6149015
[TBL] [Abstract][Full Text] [Related]
12. Reversible vincristine-related flaccid paralysis in a child with acute lymphoblastic leukemia.
Fioredda F; Micalizzi C; Lanciotti M; Dufour C; Lamba LD; Fiocchi I
Med Pediatr Oncol; 2002 Aug; 39(2):141-2. PubMed ID: 12116067
[No Abstract] [Full Text] [Related]
13. [Studies of childhood non-Hodgkin's lymphoma--treatment results with the CCLSG NHL 960 protocol. Children's Cancer and Leukemia Study Group (CCLSG)].
Tsurusawa M; Katano N; Hirota T; Ito M; Yanase T; Asami K; Koizumi S; Nakayama M; Miyawaki T; Suzumiya J; Nishikawa K; Mugisima H; Horikoshi Y; Hatae Y; Iwai A; Anami K; Kikuchi M; Osima K; Kaneko Y; Kataoka S; Tanaka A; Chin M; Taga T; Watanabe A; Fujimoto T
Rinsho Ketsueki; 1998 Nov; 39(11):1092-8. PubMed ID: 9866420
[TBL] [Abstract][Full Text] [Related]
14. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL.
Böhme A; Ganser A; Hoelzer D
Ann Hematol; 1995 Dec; 71(6):311-2. PubMed ID: 8534764
[TBL] [Abstract][Full Text] [Related]
15. Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.
Jain S; Kapoor G
Pediatr Blood Cancer; 2010 May; 54(5):783. PubMed ID: 20205256
[No Abstract] [Full Text] [Related]
16. Improved tolerance of vincristine by glutamic acid. A preliminary report.
Jackson DV; Pope EK; Case LD; Wells HB; White DR; Cooper MR; Caldwell RD; Black WR; Muss HB; Cruz JM
J Neurooncol; 1984; 2(3):219-22. PubMed ID: 6150069
[TBL] [Abstract][Full Text] [Related]
17. Treatment of stage I, IIA, IIIA1 pediatric Hodgkin disease with doxorubicin, bleomycin, vincristine and etoposide (DBVE) and radiation: a Pediatric Oncology Group (POG) study.
Tebbi CK; Mendenhall N; London WB; Williams JL; de Alarcon PA; Chauvenet AR;
Pediatr Blood Cancer; 2006 Feb; 46(2):198-202. PubMed ID: 16136581
[TBL] [Abstract][Full Text] [Related]
18. Association of CYP3A5 Expression and Vincristine Neurotoxicity in Pediatric Malignancies in Turkish Population.
Kayilioğlu H; Kocak U; Kan Karaer D; Percin EF; Sal E; Tekkesin F; Isik M; Oner N; Belen FB; Yilmaz Keskin E; Okur A; Albayrak M; Kaya Z; Pinarli FG; Yenicesu I; Karadeniz C; Oguz A; Gursel T
J Pediatr Hematol Oncol; 2017 Aug; 39(6):458-462. PubMed ID: 28697165
[TBL] [Abstract][Full Text] [Related]
19. Vincristine pharmacokinetics after repetitive dosing in children.
Gidding CE; Meeuwsen-de Boer GJ; Koopmans P; Uges DR; Kamps WA; de Graaf SS
Cancer Chemother Pharmacol; 1999; 44(3):203-9. PubMed ID: 10453721
[TBL] [Abstract][Full Text] [Related]
20. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening.
Verstappen CC; Koeppen S; Heimans JJ; Huijgens PC; Scheulen ME; Strumberg D; Kiburg B; Postma TJ
Neurology; 2005 Mar; 64(6):1076-7. PubMed ID: 15781834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
